CC-92480-MM-002
A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
- NCT03989414 ↗
- Active, not recruiting
- Celgene
- Focused
We haven't built an HCP commentary report on CC-92480-MM-002 (CC-92480, elotuzumab and 5 more in Multiple Myeloma) yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Indexed commentary on CC-92480-MM-002 so far
Podcasts, YouTube videos and X posts we have indexed that name the trial. It is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.
| Channel | Indexed | |
|---|---|---|
| Podcasts | 3 | |
| X threads | 2 |
The trial
ClinicalTrials.gov- Official title
- A Phase 1/2, Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)
- Phase
- Phase 1/Phase 2
- Status
- Active, not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- CC-92480; Bortezomib; Dexamethasone; Daratumumab; Carfilzomib; Elotuzumab; Isatuximab; Carfilzomib
- Arms
- Cohort A: CC-92480 with bortezomib and dexamethasone · Experimental
- Cohort C: CC-92480 with carfilzomib and dexamethasone · Experimental
- Cohort H: CC-92480 with elotuzumab and dexamethasone · Experimental
- Cohort I: CC-92480 with isatuximab and dexamethasone · Experimental
- Cohort D: CC-92480 with bortezomib and dexamethasone · Experimental
- Cohort F: CC-92480 with carfilzomib and dexamethasone · Experimental
- Cohort J: CC-92480 with elotuzumab and dexamethasone · Experimental
- Cohort K: CC-92480 with isatuximab and dexamethasone · Experimental
- Cohort G: CC-92480 with bortezomib and dexamethasone · Experimental
- Subcohort B1: CC-92480 with daratumumab and dexamethasone · Experimental
- Subcohort B2: CC-92480 with daratumumab and dexamethasone · Experimental
- Subcohort B3: CC-92480 with daratumumab and dexamethasone · Experimental
- Subcohort E1: CC-92480 with daratumumab and dexamethasone · Experimental
- Subcohort E2: CC-92480 with daratumumab and dexamethasone · Experimental
- Subcohort E3: CC-92480 with daratumumab and dexamethasone · Experimental
- Enrollment
- 424 (estimated)
- Primary outcomes
- Recommended Dose
- Recommended regimen as measured by dose-limiting toxicities
- Number of participants with Adverse Events (AEs)
- Overall response rate (ORR)
- Sponsor
- Celgene
- Start
- Sep 30, 2019
- Primary completion
- Nov 30, 2026 (estimated)
- Results posted
- No
- Registry record
- NCT03989414 · updated Nov 29, 2024